Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tipiracil/trifluridine - Taiho Pharmaceutical

Next Previous
Drug Profile

Tipiracil/trifluridine - Taiho Pharmaceutical

Alternative Names: FTD/TPI; Lonsurf; Orcantas; S 95005; S 95005/TAS-102; T15, T20; T15/T20; TAS-102; TAS-102/S-95005; Tipiracil-hydrochloride/trifluridine; Trifluridine/tipiracil; Trifluridine/tipiracil hydrochloride

Latest Information Update: 07 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiho Pharmaceutical
  • Developer Amgen; Baylor Research Institute; Emory University; Ipsen; Servier; Taiho Oncology; Taiho Pharmaceutical; TTY Biopharm; University of Florida; University of Wisconsin-Madison
  • Class Antineoplastics; Nucleosides; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Thymidine phosphorylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Colorectal cancer; Gastric cancer
  • Phase II Bladder cancer; Cholangiocarcinoma; Neuroendocrine tumours; Oesophageal cancer; Pancreatic cancer; Small cell lung cancer; Squamous cell cancer
  • Phase I/II Gastrointestinal cancer
  • No development reported Solid tumours

Most Recent Events

  • 18 Jan 2024 Pharmacodynamics and efficacy data from phase I trial in Colorectal cancer presented at Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
  • 18 Jan 2024 Updated adverse events data from a phase III clinical trial in Colorectal cancer presented at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
  • 05 Jan 2024 Indiana University and Taiho technology terminates a phase I trial in Pancreatic cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO) due to neulasta difficulties and other complications (NCT04046887)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top